Efficacy and safety of standardized extract of Trigonella foenum-graecum l seeds as an adjuvant to L-dopa in the management of patients with Parkinson's disease

Phytotherapy Research

Volumn 28, Issue 2, 2014, Pages 172-178

  Nathan, J ^a   Panjwani, Siddika ^a   Mohan, V ^b   Joshi, Veena ^b   Thakurdesai, Prasad Arvind ^b  

^a Shushrusha Hospital   (India)

^b Indus Biotech Private Limited   (India)

Author keywords

fenugreek; Hoehn and Yahr (H Y) staging; Parkinson's disease; Trigonella foenum graecum; Trigonelline; UPDRS

Indexed keywords

FENUGREEK; HOEHN AND YAHR (H&Y) STAGING; PARKINSON'S DISEASE; TRIGONELLA FOENUM-GRAECUM; TRIGONELLINE; UPDRS;

ADJUVANTS, PHARMACEUTIC; AGED; DIHYDROXYPHENYLALANINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PLANT EXTRACTS; SEEDS; TRIGONELLA;

EID: 84893748412     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4969     Document Type: Article

References (52)

1. Ahmadiani A, Javan M, Semnanian S, Barat E, Kamalinejad M,. 2001. Anti-inflammatory and antipyretic effects of Trigonella foenum-graecum leaves extract in the rat. J Ethnopharmacol 75: 283-286.
2. Anuradha CV, Ravikumar P,. 2001. Restoration on tissue antioxidants by fenugreek seeds (Trigonella Foenum graecum) in alloxan-diabetic rats. Ind J Physiol Pharmacol 45: 408-420.
3. Barrett B, Brown D, Mundt M, Brown R,. 2005. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Making 25: 250-261.
4. Beal MF,. 2003. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 991: 120-131.
5. Berglund T,. 1994. Nicotinamide, a missing link in the early stress response in eukaryotic cells: A hypothesis with special reference to oxidative stress in plants. FEBS Lett 351: 145-149.
6. Berglund T, Kalbin G, Strid A, Rydstrom J, Ohlsson AB,. 1996. UV-B- and oxidative stress-induced increase in nicotinamide and trigonelline and inhibition of defensive metabolism induction by poly(ADP-ribose)polymerase inhibitor in plant tissue. FEBS Lett 380: 188-193.
7. Caplan L,. 2007. How well does" evidence-based" medicine help neurologists care for individual patients? Rev Neurol Dis 4: 75.
8. Cotzias GC, Papavasiliou PS, Gellene R,. 1969. Modification of Parkinsonism - chronic treatment with L-dopa. N Engl J Med 280: 337-345.
9. Devasena T, Menon VP,. 2002. Enhancement of circulatory antioxidants by fenugreek during 1,2-dimethylhydrazine-induced rat colon carcinogenesis. J Biochem Mol Biol Biophys 6: 289-292.
10. Devasena T, Menon VP,. 2007. Fenugreek seeds modulate 1,2-dimethylhydrazine-induced hepatic oxidative stress during colon carcinogenesis. Ital J Biochem 56: 28-34.
11. Dunnett SB, Bjorklund A,. 1999. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399: A32-A39.
12. Fahn S, Elton RL,. 1987. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In Recent Developments in Parkinson's Disease, S Fahn, CD Marsden, DB Calne, M Goldstein, (eds). Macmillan Health Care Information: Florham Park, NJ, 153-164.
13. Gaur V, Maheshwari A, Thakurdesai PA, Bodhankar SL,. 2008. Anti-parkinson effect of trigonelline in laborotory animals. In International Structural Neuroscience Conference on Peptides, Nagpur: Department of Pharmaceutical Sciences, Nagpur University, p. 19.
14. Gaur V, Bodhankar SL, Mohan V, Thakurdesai PA,. 2013. Neurobehavioral assessment of hydroalcoholic extract of Trigonella foenum-graecum L. in rodent models of Parkinson's disease. Pharm Biol In Press. DOI: 10.3109/13880209.2012. 747547
15. Goberman AM, Blomgren M,. 2003. Parkinsonian speech disfluencies: effects of L-dopa-related fluctuations. J Fluency Disord 28: 55-70.
16. Goetz CG, Poewe W, Rascol O, et al,. 2004. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19: 1020-1028.
17. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC,. 1984. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467-469.
18. Hoehn MM, Yahr MD,. 1967. Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
19. Hong BN, Yi TH, Park R, Kim SY, Kang TH,. 2008. Coffee improves auditory neuropathy in diabetic mice. Neurosci Lett 441: 302-306.
20. Houghton PJ, Howes MJ,. 2005. Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. Neurosignals 14: 6-22.
21. Jaeschke R, Singer J, Guyatt GH,. 1989. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10: 407-415.
22. Kaviarasan S, Ramamurty N, Gunasekaran P, Varalakshmi E, Anuradha CV,. 2006. Fenugreek (Trigonella foenum graecum) seed extract prevents ethanol-induced toxicity and apoptosis in Chang liver cells. Alcohol Alcohol 41: 267-273.
23. Li FQ, Lu XZ, Liang XB, et al,. 2004. Triptolide, a Chinese herbal extract, protects dopaminergic neurons from inflammation-mediated damage through inhibition of microglial activation. J Neuroimmunol 148: 24-31.
24. Markham CH, Diamond SG,. 1981. Evidence to support early levodopa therapy in Parkinson disease. Neurology 31: 125-131.
25. Mattila PM, Rinne JO, Helenius H, Roytta M,. 1999. Neuritic degeneration in the hippocampus and amygdala in Parkinson's disease in relation to Alzheimer pathology. Acta Neuropathol (Berl) 98: 157-164.
26. Mishkinsky J, Joseph B, Sulman FG,. 1967. Hypoglycaemic effect of trigonelline. Lancet 2: 1311-1312.
27. Muralidhara, NK, Viswanatha S, Ramesh BS,. 1999. Acute and subchronic toxicity assessment of debitterized fenugreek powder in the mouse and rat. Food Chem Toxicol 37: 831-838.
28. Nadkarni KM, (ed.) 1994. The Indian materia medica, 3rd edn. Vol. 1. Popular Prakashan: Bombay.
29. National Collaborating Centre for Chronic Conditions. 2006. Parkinson's Disease. In National clinical guideline for diagnosis and management in primary and secondary care. Royal College of Physicians: London, 1-242.
30. Olanow CW, Watts RL, Koller WC,. 2001. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56: S1-S88.
31. Opdyke D,. 1978. Fenugreek absolute. Food Cosmet Toxicol 16: 755.
32. Organization for Economic Co-operation and Development. 2001. Guidance Document on Acute Oral Toxicity Testing. Environment Directorate, OECD: Paris, 1-24.
33. Papapetropoulos S, Basel M, Mash DC,. 2007. Dopaminergic innervation of the human striatum in Parkinson's disease. Mov Disord 22: 286-288.
34. Patil SP, Niphadkar PV, Bapat MM,. 1997. Allergy to fenugreek (Trigonella foenum graecum). Ann Allergy Asthma Immunol 78: 297-300.
35. Preet A, Gupta BL, Siddiqui MR, Yadava PK, Baquer NZ,. 2005. Restoration of ultrastructural and biochemical changes in alloxan-induced diabetic rat sciatic nerve on treatment with Na3VO4 and Trigonella - a promising antidiabetic agent. Mol Cell Biochem 278: 21-31.
36. Rao PU, Sesikeran B, Rao PS, Naidu AN, Rao VV, Ramachandran E,. 1996. Short term nutritional and safety evaluation of fenugreek. Nutr Res 16: 1495-1505.
37. Rascol O,. 2009. " Disease-modification" trials in Parkinson disease: target populations, endpoints and study design. Neurology 72: S51-S58.
38. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C,. 2002. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 359: 1589-1598.
39. Ruberg M, Scherman D, Javoy-Agid F, Agid Y,. 1995. Dopamine denervation, age of onset, and Parkinson's disease. Neurology 45: 392.
40. Saravanan R, Pari L,. 2005. Antihyperlipidemic and antiperoxidative effect of Diasulin, a polyherbal formulation in alloxan induced hyperglycemic rats. BMC Complement Altern Med 5: 1-8.
41. Shah S, Bodhankar SL, Badole SL, Kamble HV, Mohan V,. 2006. Effect of trigonelline: an active compound from Trigonella foenumgraecum linn. in alloxan induced diabetes in mice. J Cell Tissue Res 6: 585-590.
42. Sharma R, Sarkar A, Hazra D, Misra B, Singh J, Maheshwari B,. 1998. Toxicological evaluation of fenugreek seeds: a long term feeding experiment in diabetic patients. Phytother Res 10: 519-520.
43. Shif M, Kempster PA,. 1994. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease. Clin Exp Neurol 31: 38-42.
44. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ,. 2010. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 67: 64-70.
45. Shults CW, Oakes D, Kieburtz K, et al,. 2002. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59: 1541-1550.
46. Silva MA, Mattern C, Hacker R, Tomaz C, Huston JP, Schwarting RK,. 1997. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: On the role of benserazide pretreatment. Synapse 27: 294-302.
47. Thakran S, Baquer NZ,. 2003. Oral administration of orthovanadate and Trigonella foenum graecum seed powder restore the activities of mitochondrial enzymes in tissues of alloxan-induced diabetic rats. Mol Cell Biochem 247: 45-53.
48. Tohda C, Nakamura N, Komatsu K, Hattori M,. 1999. Trigonelline-induced neurite outgrowth in human neuroblastoma SK-N-SH cells. Biol Pharm Bull 22: 679-682.
49. Tuite P, Riss J,. 2003. Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin Investig Drugs 12: 1335-1352.
50. US Food and Drug Administration. 2005. Guidance for Industry, Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. In Center for Drug Evaluation and Research, USFDA, US Department of Health and Human Services. http://wwwfdagov/cder/guidance/indexhtm
51. Vyas S, Agrawal RP, Solanki P, Trivedi P,. 2008. Analgesic and anti-inflammatory activities of Trigonella foenum-graecum (seed) extract. Acta Pol Pharm 65: 473-476.
52. Yen WJ, Wang BS, Chang LW, Duh PD,. 2005. Antioxidant properties of roasted coffee residues. J Agric Food Chem 53: 2658-2663.